News & Events

Category: News

Join the Vivli Team: Project Manager, Data Scientist

Project Manager, Data Scientist

VIVLI, the Center for Global Clinical Research Data, is seeking a Project Manager, Data Scientist. Vivli is a mission-focused non-profit, and we are looking for a project manager with clinical research data experience who can take on our data-focused projects.

Location: Remote, working core hours of 9am-5pm Eastern time zone, with the ability to travel 3-4 times per year.

Salary: Commensurate with experience

Reports to: Senior Program Manager

Job Position ID: VIVLI-2026-10-DS

The Project Manager, Data Scientist will be responsible for leading projects from initiation through closeout across grant-funded programs and data-focused projects. Key responsibilities include:

  • Manage data-focused and internal operations projects from initiation through closeout, maintaining project documentation and tracking work in a ticket-based system
  • Track deliverables, milestones, and budgets across grant-funded programs, and prepare funder reporting to deadline.
  • Manage external commitments and agreements with funders, data contributors, and vendors.
  • Coordinate governance bodies and serve as the day-to-day point of contact between technical, operational, and program teams.
  • Identify risks early, escalate them in writing, and communicate scope or timeline changes before deadlines are missed.
  • Own the recurring reporting cycle for grant-funded programs, producing each report to the funder’s format and deadline.
  • Build and maintain dashboards and recurring reports, automating them where sensible rather than rebuilding each cycle.
  • Perform additional duties as assigned to support organizational goals.

Qualification Requirements

  • Bachelor’s degree in health sciences, life sciences, statistics, data analysis, IT, or a related field.
  • 2-4 years coordinating or managing multiple projects in health, research, or data settings.
  • Experience analyzing clinical research data
  • Hands-on data work: pulling, cleaning, and reconciling data from more than one system using scientific data analysis software such as R, Stata, SAS or Python.
  • Proactive ownership of timelines: surfacing blockers early and keeping stakeholders aligned
  • Comfortable maintaining project documentation and tracking work in a ticket-tracked system such as Jira and Zendesk, and proficient in Microsoft Office Suite.
  • Exceptional attention to detail and consistency.
  • Excellent written and oral communication skills.
  • Must be authorized to work in the United States.

Strongly Preferred

  • Master’s degree in biostatistics, statistics, epidemiology, or data analysis, or equivalent experience analyzing clinical trial data.
  • Experience in clinical research data sharing, secondary data use, or research data repositories.
  • Grant reporting experience, including tracking delivery against funded milestones.
  • Experience in academic, industry, government, or research institutions.

Nice to Have

  • Building, supporting, and enhancing AI-assisted workflows in a regulated context.
  • Building dashboards or automated reporting in any tooling.
  • Familiarity with FAIR data principles and research data management practice.
  • Understanding of clinical trials processes and/or clinical data management.
  • Knowledge of GDPR.

What We Offer

  • Comprehensive benefits package, including health, dental, and vision insurance.
  • Opportunities for professional growth and development, including formal training in output checking.
  • Flexible work arrangements.
  • A dynamic and collaborative workplace culture.
  • Meaningful work that makes a real difference in the world.

How to Apply

Interested candidates are required to submit their resume and a cover letter to hr@vivli.org with the Job Position ID “VIVLI-2026-10-DS” included in the subject line.

Vivli is an equal opportunity employer.

 

Join the Vivli Team: Project Manager

Project Manager

VIVLI, the Center for Global Clinical Research Data, is seeking a Project Manager. Vivli is a mission-focused non-profit, and to help manage our continued growth we are looking for a project manager to lead delivery across our grant-funded programs, platform projects, and internal initiatives.

Location: Remote, working core hours of 9am-5pm Eastern time zone, with the ability to travel 3-4 times per year.

Salary: Commensurate with experience

Reports to: Senior Program Manager

Job Position ID: VIVLI-2026-10-PM

The Project Manager will be responsible for leading projects from initiation through closeout across grant-funded programs, software and platform work, and internal operations. Key responsibilities include:

  • Lead planning, execution, and delivery of projects through to formal closeout, maintaining project documentation and tracking in Jira and Confluence.
  • Deliver software and Vivli platform projects alongside the product manager, owning scheduling and delivery.
  • Track deliverables, milestones, and budgets across grant-funded programs, and prepare funder reporting to deadline.
  • Manage external commitments and agreements with funders, data contributors, and vendors.
  • Coordinate governance bodies and serve as the day-to-day point of contact between technical, operational, and program teams.
  • Identify risks early, escalate them in writing, and communicate scope or timeline changes before deadlines are missed.
  • Lead internal tooling and process improvement projects.
  • Perform additional duties as assigned to support organizational goals.

Qualification Requirements

  • Minimum Bachelor’s degree in health sciences, IT, project management, or a related field.
  • 3-5 years managing projects in health, science, or IT-related fields
  • Experience running projects through conception to formal closeout, including the documentation each stage requires.
  • Experience delivering projects with software or technical components.
  • Proactive ownership of timelines: surfacing blockers early and keeping stakeholders aligned
  • Proficient maintaining project documentation and tracking work in a ticket-tracked system such as Jira and Zendesk, and proficient in Microsoft Office Suite.
  • Excellent written and oral communication skills.
  • Excellent organizational skills and the ability to manage multiple priorities simultaneously.
  • Must be authorized to work in the United States.

Strongly Preferred

  • Project management on software development projects, ideally in a Product Owner role owning scheduling and delivery.
  • PMP certification or equivalent experience.
  • Managing external commitments and agreements with funders, contributors, and vendors.
  • Experience with the clinical data sharing ecosystem
  • Familiarity with software delivery artifacts: requirements, user stories, acceptance criteria, test cases, and release planning.
  • Experience in academic, industry, government, or research institutions.
  • Grant or contract management experience.

Nice to Have

  • Building, supporting, and enhancing AI-assisted workflows in a regulated context.
  • Understanding of clinical trials processes and/or clinical data management.
  • Knowledge of GDPR.
  • Technical and grant writing experience.

What We Offer

  • Comprehensive benefits package, including health, dental, and vision insurance.
  • Opportunities for professional growth and development.
  • Flexible work arrangements.
  • A dynamic and collaborative workplace culture.
  • Meaningful work that makes a real difference in the world.

How to Apply

Interested candidates are required to submit their resume and a cover letter to hr@vivli.org with the Job Position ID “VIVLI-2026-10-PM” included in the subject line.

Vivli is an equal opportunity employer.

GARDP Joins Vivli as New Member to Share its Data

“We are delighted to welcome the Global Antibiotic Research & Development Partnership (GARDP) as a member of Vivli and Vivli’s AMR Register” shared Rebecca Li, Vivli CEO. “GARDP’s leadership in addressing antimicrobial resistance makes its commitment to data sharing especially significant. We look forward to working together to broaden access to valuable clinical research data and to support the evidence needed to develop effective treatments for drug-resistant infections.”

 “Antimicrobial resistance is a global challenge that demands collaboration and transparency across the research ecosystem,” said Justin Green, Medical Director at GARDP. “Through our participation in Vivli and the AMR Register, GARDP is reinforcing its commitment to responsible data sharing and to advancing the science needed to deliver new treatment options for drug-resistant infections. We hope the data will support researchers worldwide and help ensure that effective treatments reach the people who need them most.”

GARDP is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. Its public-private partnership model integrates affordability, appropriate use, and sustainable access throughout the development process, with a particular focus on high-burden countries and vulnerable populations, including newborns.

By joining Vivli and participating in Vivli’s AMR Register, GARDP will help expand access to clinical research data and strengthen the global evidence base for addressing antimicrobial resistance.

For more information about the conditions for accessing GARDP data, please visit their member page. To learn more about membership in Vivli, visit vivli.org/members/become-a-member/ .

Meet the 2026 Vivli Global Ambassadors

Vivli is pleased to announce the 2026 cohort of Global Ambassadors, a group of researchers using shared clinical research data to answer important scientific questions and champion the value of data reuse within their research communities. The Global Ambassador Program supports researchers in extending the reach and impact of work emerging from secondary analyses. Ambassadors share their findings and perspectives through conferences, publications, professional networks, and other forums, contributing to broader conversations about responsible data sharing and reuse. “We are excited to welcome this new group of Ambassadors and support them in sharing both their research and their experiences working with shared data,” said Rebecca Li, Vivli CEO. “Researchers who put existing data to new use are some of the strongest advocates for data sharing because they can show firsthand the new questions, findings, and collaborations that access can make possible.”

Dr. Ruanne Barnabas
Dr. Ruanne Barnabas Massachusetts General Hospital, USA
Dr. Diego Chowell
Dr. Diego Chowell Icahn School of Medicine at Mount Sinai, USA
Robin Gal
Robin Gal Jaeb Center for Health Research
Dr. Ashley Hopkins
Dr. Ashley Hopkins Flinders University, Australia
Dr. Jennifer Lees
Dr. Jennifer Lees University of Glasgow, Scotland
Dr. David McAllister
Dr. David McAllister University of Glasgow, Scotland
Dr. Stephen Opiyo
Dr. Stephen Opiyo The Ohio State University
Dr. Vivek Rudrapatna
Dr. Vivek Rudrapatna University of California, San Francisco
Dr. Jonas Saal
Dr. Jonas Saal University Hospital Bonn, Germany
Dr. Marco Valgimigli
Dr. Marco Valgimigli Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland
Dr. Youssef Zeidan
Dr. Youssef Zeidan Baptist Health South Florida, USA

The 2026 cohort builds on the work of Vivli’s inaugural Ambassadors, who used data accessed through Vivli to advance research across cancer, cardiovascular disease, diabetes, and clinical research methodology. Over the course of the year, the 2025 Ambassadors published new findings, presented their work to research communities around the world, pursued new analyses, and helped broaden the conversation around responsible data sharing and reuse. We congratulate this year’s Ambassadors on their selection and look forward to following their work over the coming year.

Introducing the Alzheimer’s Trials Data Discovery Challenge

We are proud to announce the launch of the Alzheimer’s Trials Data Discovery Challenge — a $75,000 research competition powered by the Alzheimer’s Disease Data Initiative and Vivli, and supported by Alzheimer’s Research UK.

The challenge is built around a fully harmonized control-arm dataset drawn from 11 Alzheimer’s trials across five pharmaceutical sponsors: AstraZeneca, Lilly, Johnson & Johnson, Roche, and Takeda. It brings together 7,089 placebo-arm participants and more than 20 years of data — never before analyzed at this scale.

Three research tracks address questions newly answerable at this scale: sex differences in Alzheimer’s disease, rates of progression, and subtyping and heterogeneity. Up to 24 teams will participate, with $25,000 awarded to the first-place team in each track. Winning teams will also have the opportunity to publish findings in a high-impact journal and present at a major Alzheimer’s conference.

All analysis takes place within Vivli’s secure, cloud-based research environment. Teams must include a PI sponsor and a statistician at minimum.

The first letter of intent deadline is September 1, 2026. Winners will be announced in Spring 2027.

Learn more and apply →

Vivli Europe Webinar: Understanding the European Health Data Space (EHDS) and the Secondary Use of Data (SUD): Requirements, Challenges, and the Path Forward

Date/Time: August 19, 2026 (9:00 AM ET | 3:00 PM CET)

Presenters: Jennifer O’Callaghan, Executive Director of Vivli Europe

The EU’s European Health Data Space (EHDS) Regulation establishes a framework for how health data can be accessed and reused to drive research, innovation, and policy. While the regulation entered into force in March 2025, its specific rules regarding the secondary use of data (SUD) are set to take effect in March 2029. In this session, Jennifer O’Callaghan, Executive Director of Vivli Europe, provides an introduction to the EHDS SUD mandate and its implications for both data holders and data users. She will examine the processes for making health data available for secondary use, highlight areas where the framework is still evolving, and address the key questions remaining as implementation begins.

No prior knowledge of EHDS is required; this session is designed for anyone seeking a clear overview of the EHDS SUD framework and its future trajectory.

Register Here

Vivli Platform Version 4.0 Now Available

Version 4.0 of the Vivli platform was released June 27, 2026 and is now available to users. 

Release 4.0 includes several key improvements designed to enhance the user experience and support more secure, connected workflows:

    • Improved and updated platform navigation
    • Multi-Factor Authentication (MFA) enabled for all users to further enhance security

All Vivli resources and how to guides have been updated to reflect the latest release 

“We are delighted to have added MFA to the Vivli platform to further enhance our security posture,” said Robert Conklin, Vivli Chief Technology Officer. 

 

The Vivli Global Ambassador Program: Highlights from the Inaugural Cohort

Global researchers used shared trial data to advance work in cancer, diabetes, and clinical trial design.

The Vivli Global Ambassador Program brought together a diverse group of researchers selected for their commitment to data transparency and leadership in advancing clinical research around the world. Through their use of shared clinical research data, these Ambassadors help promote responsible data sharing and reuse within their fields. Over the past year, the inaugural cohort has shown how data available through Vivli can be incorporated into active research programs to generate new findings, support scientific exchange, and create new opportunities for collaboration. One of the most important contributions of the program has been visibility. For many researchers, data reuse remains unfamiliar despite growing expectations around data sharing. Ambassadors helped bridge that gap by sharing their experiences at major scientific meetings and academic seminars across four continents, from the European Society for Radiation Oncology meeting in Vienna and the International Congress on Lung Cancer in Barcelona, to the Princess Takamatsu Symposium in Tokyo, the IATDMCT meeting in Singapore, and the Vivli Annual Meeting in Cambridge, Massachusetts. In each setting they discussed both the outcomes of their work and the practical realities of conducting secondary research, walking colleagues through everything from the data application process to study design, and introducing investigators across disciplines to approaches that are increasingly shaping the research landscape. What follows is a closer look at the work of the individual ambassadors.
Dr. David McAllister (University of Glasgow, Scotland) used Vivli individual participant data (IPD) to drive a productive year of diabetes and trial-methodology research, publishing four peer-reviewed papers in 2025. These included a network meta-analysis of age and sex differences in the efficacy of treatments for type 2 diabetes, published in JAMA, and an IPD meta-analysis of frailty across trials of glucose-lowering therapies, published in PLOS Medicine, alongside further work on trial representativeness and trial attrition. Beyond his own publications, Dr. McAllister presented on Vivli as a research resource at the universities of Bristol, Edinburgh, and Glasgow and at an EU doctoral training network, is supervising PhD students working directly with Vivli IPD, and drew on his established relationship with Vivli to strengthen several major grant applications and new institutional collaborations.
Dr. Jonas Saal (University Hospital Bonn, Germany) focused his ambassador year on immuno-oncology biomarkers, presenting Vivli-derived analyses of the modified Glasgow Prognostic Score (mGPS) and progressive-disease classification — including its use in selecting patients for treatment beyond progression — at oncology and urology meetings such as the DGHO annual meeting and the AIO Herbstkongress, where his work earned a Young Investigator Award. His written output included a review in the European Journal of Cancer on sodium and immunotherapy and a Frontiers in Immunology article on mGPS in hepatocellular carcinoma, building on a body of Vivli-based publications spanning immunotherapy beyond progression, metastatic urothelial carcinoma, and metastatic renal cell carcinoma. He described Vivli as “an enabler of collaborative, methodologically rigorous secondary research.”
Dr. Youssef Zeidan (Baptist Health South Florida, USA) advanced his breast cancer research program through Vivli, completing a pooled analysis of the TRYPHAENA and NeoSphere trials examining radiation therapy in clinically node-positive, HER2-positive breast cancer. “The VIVLI Ambassador program provided an outstanding opportunity to support my ongoing breast cancer research initiatives,” he wrote. The findings were presented at the European Society for Radiation Oncology (ESTRO) annual meeting in Vienna and published in BMC Cancer. The project also became a mentorship opportunity: the trainee who led the analysis, a medical student, went on to match into radiation oncology at Stanford. Dr. Zeidan’s continued partnership with Vivli has since produced a newly approved project applying the same approach to triple-negative breast cancer.
Dr. Ashley Hopkins (Flinders University, Australia) drew on Vivli-accessed data to investigate how concomitant medicines and patient characteristics shape cancer outcomes, with written outputs including studies on concomitant medicines and patient-reported outcomes in chronic lymphocytic leukemia, a large-scale IPD meta-analysis of sex-based differences in solid-tumour outcomes (accepted in the Journal of the National Cancer Institute), and a breast-cancer outcomes paper led by a member of his team, Dr. Bradley Menz. Dr. Hopkins shared this work through an invited talk at IATDMCT 2025 in Singapore and an industry session on AI in oncology, while his engagement with the South Australian Comprehensive Cancer Network is now feeding directly into a new collaborative Vivli application on youth-onset cancers — and contributed to a PhD completion incorporating Vivli-derived work.
Dr. Diego Chowell (Icahn School of Medicine at Mount Sinai, USA) championed responsible data sharing within the AI and computational immuno-oncology community, weaving the case for transparent, well-governed clinical and trial datasets into talks on tumor evolution, immune recognition, and immunotherapy response prediction at Princeton University, the Princess Takamatsu Symposium in Tokyo, the International Congress on Lung Cancer in Barcelona, and a scientific seminar at VHIO. His central message, that robust, externally validated AI models depend on access to shared, reusable data, resonated with audiences of oncologists, computational biologists, and trialists. He is now developing a Vivli data request to externally validate his SCORPIO model for immune-risk prediction and trial stratification, laying the groundwork for a future Vivli-enabled analysis.
Dr. Marco Valgimigli (Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland) carried the case for responsible clinical-trial data sharing into the interventional cardiology and cardiovascular pharmacology community, anchored in his own Vivli-enabled work. As Lead Investigator of the PANTHER collaborative initiative — an individual patient data meta-analysis comparing P2Y12 inhibitor monotherapy with aspirin for secondary prevention in coronary artery disease, conducted using datasets accessed through Vivli and published in the Journal of the American College of Cardiology — he was able to present a completed, peer-reviewed project as a concrete proof of concept. He brought that example to talks and discussions at ESC Congress 2025 in Madrid, the inaugural EAPCI Summit 2026 in Munich, and FOKUS HERZ BERN 2026, and to direct engagement with trainees and collaborators at Cardiocentro Ticino, walking colleagues through the full arc of a Vivli data request to show how shared participant-level data enable rigorous, academically independent secondary research.
As the first year of the program concludes, the cohort’s accomplishments reflect a broader shift toward a research culture in which data are not only shared, but actively reused. Their work highlights the continued value of clinical research data and the new knowledge that can emerge when those data remain available to the scientific community.

Vivli Data Contributor Spotlight: UCSF’s Kaitlin Yee on Navigating Data Sharing Across a Multi-Study Research Initiative

Kaitlin Yee
Research Coordinator, University of California San Francisco (UCSF) Department of Orthopaedic Surgery

Chronic low back pain affects one in five adults in the United States and remains one of the leading causes of disability worldwide. REACH, UCSF’s Core Center for Patient-Centric, Mechanistic Phenotyping in Chronic Low Back Pain, is funded through NIH HEAL and embedded within the Back Pain Consortium (BACPAC).

Established in 2019 with nearly $30 million in NIH funding, the Center runs two large observational cohorts with overlapping participant populations: comeBACK, an in-person study of 450 adults phenotyped across four University of California sites, and BACKHOME, a fully remote nationwide e-cohort of roughly 3,000 adults, the largest prospective remote registry of chronic low back pain to date. Between the two cohorts, there are nearly 3,450 participants.

Each cohort, along with the REACH center grant, had to be shared as its own data package, a condition of their federal funding. When NIH HEAL designated Vivli as its recommended repository, Kaitlin Yee, a Research Coordinator at UCSF’s Department of Orthopaedic Surgery, took on the submission process for all three.

“It was definitely a bit overwhelming at first,” Kaitlin said, “just in terms of where to start and exactly what was required of us.”  

Each submission required four elements: a protocol, individual participant data (IPD), a data dictionary, and a statistical analysis plan. She started with Vivli’s submission checklist and a HEAL-specific tutorial video, which walked through each step, including how to connect each study’s DOI directly to the NIH HEAL Data Platform, so the data is findable from either direction. 

“You can go to the HEAL platform and the DOI for our study is linked,” she said. “I thought that was actually pretty neat.” 

Three submissions and dozens of files called for a system. The REACH team established a simple file naming convention that tied each data package to its corresponding publication, keeping the uploads organized across multiple cycles as the volume grew.

Kaitlin worked closely throughout the process with Sarah Sweet, Vivli’s Senior Clinical Research Manager. When a submission needed to be reset mid-upload, it was handled the same day. 

“Sarah has been amazing. We’ve been talking back and forth ever since we started. She’s been so responsive. I really don’t think we’d be where we are without her.” 

All three studies are now live on Vivli and linked to the HEAL Data Platform, making data from close to 3,450 participants available to researchers worldwide. For a condition that affects one in five adults and has long resisted easy answers, that reach is the payoff: every team that builds on this data gets closer to understanding chronic low back pain and how to treat it. 

The datasets shared by the REACH team are available on Vivli. To learn more about sharing your research data, visit https://vivli.org/resources/sharedata/ 

Merck KGaA, Darmstadt, Germany Joins Vivli as New Member to Share its Data

“We are excited to welcome Merck KGaA, Darmstadt, Germany to the Vivli platform,” shared Vivli CEO Rebecca Li. “Their membership meaningfully expands the data available to researchers and reflects the growing momentum behind responsible clinical trial data sharing.”

Founded in 1668, Merck KGaA, Darmstadt, Germany is the world’s oldest operating pharmaceutical and chemical company. Headquartered in Darmstadt, Germany, the company operates across three business sectors: healthcare, life science, and electronics — and has a presence in 66 countries. Its healthcare division focuses on developing therapies for difficult-to-treat conditions across disciplines such as oncology, neurology, and immunology. In the United States and Canada, the company’s healthcare business operates as EMD Serono.  

For more information about the conditions for accessing Merck KGaA, Darmstadt, Germany data, please visit their member page. To learn more about membership in Vivli, visit our webpage.